| Item | What the label or Lilly says |
|---|---|
| Molecule | Tirzepatide, a GIP receptor and GLP-1 receptor agonist |
| Approved uses | Weight reduction and long-term maintenance (adults with obesity, or overweight plus a weight-related condition); moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity |
| Schedule | Once weekly, under the skin |
| Dose range | 2.5 mg start; maintenance 5, 10 or 15 mg for weight; 10 or 15 mg for OSA; maximum 15 mg |
| Forms on the label | Single-dose pen, single-dose vial, multi-dose vial (4 doses), KwikPen (4 doses) |
| Boxed warning | Risk of thyroid C-cell tumors |
| Self-pay (KwikPen) | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with each refill within 45 days) |
| Medicare GLP-1 Bridge | KwikPen only; $50 copay for eligible enrollees |
What is Zepbound approved for?
Zepbound has two FDA-approved uses, both alongside a reduced-calorie diet and more physical activity. The first is reducing excess body weight and keeping it off long term in adults with obesity, or adults with overweight who have at least one weight-related condition.
The second, added on December 20, 2024, is treating moderate-to-severe obstructive sleep apnea in adults with obesity. FDA's announcement described two 52-week trials in 469 adults without type 2 diabetes, one in people using positive airway pressure and one in people who could not or would not use it. The sleep apnea angle has its own page: GLP-1 drugs and sleep apnea.
Zepbound itself was first approved on November 8, 2023, according to Drugs@FDA. The molecule is also sold as Mounjaro for type 2 diabetes; the differences are laid out in Mounjaro vs Zepbound.
How is Zepbound dosed?
You start at 2.5 mg once a week for 4 weeks, then move to 5 mg. The label treats 2.5 mg as a starting dose only, not a maintenance dose.
- After 5 mg, the dose can rise in 2.5 mg steps, with at least 4 weeks on each dose.
- For weight, the label lists 5 mg, 10 mg or 15 mg as maintenance doses.
- For sleep apnea, it lists 10 mg or 15 mg.
- The maximum for every use is 15 mg a week.
The slow climb is there to reduce stomach and bowel side effects. If you miss a dose, the label allows taking it within 4 days (96 hours); after that you skip it and keep your usual day. Your prescriber sets the actual schedule, and may hold you at a lower dose if a higher one is hard to tolerate.
Which forms does Zepbound come in?
The current label lists four presentations, all with the same six strengths from 2.5 mg to 15 mg.
- Single-dose pen: an autoinjector used once.
- Single-dose vial: you draw up the dose with a syringe.
- Multi-dose vial: holds 4 weekly doses.
- KwikPen: a single-patient pen holding 4 weekly doses. The label says it should never be shared, even with a new needle, and is not recommended for self-injection by people who are visually impaired.
The form matters for cost and coverage. Lilly's self-pay ladder below and the Medicare Bridge both refer to the KwikPen.
What does the boxed warning say?
Tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it does so in people. The label therefore says not to use Zepbound if you or a family member has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Stomach and bowel effects are the most common problems. In the label's pooled weight trials, nausea was reported by 25% to 29% of people on Zepbound versus 8% on placebo, diarrhea by 19% to 23% versus 8%, and vomiting by 8% to 13% versus 2%. The label also warns about pancreatitis, gallbladder disease, kidney injury from dehydration, serious allergic reactions and aspiration during anesthesia. The full list is in our side-effects guide.
What does Zepbound cost if you pay yourself?
Lilly's self-pay KwikPen price depends on the dose and on how quickly you refill. The figures below come from Lilly's terms as read October 15, 2026.
| Dose | Refill within 45 days | Refill later than 45 days |
|---|---|---|
| 2.5 mg | $299 | $299 |
| 5 mg | $399 | $399 |
| 7.5 mg | $449 | $499 |
| 10 mg, 12.5 mg, 15 mg | $449 | $699 |
Three rules change the math. A "month" is one KwikPen, which is 28 days of doses. The savings card covers 11 fills per calendar year. And the current savings end December 31, 2026, so 2027 pricing was not published when we checked.
As arithmetic only: a person who starts at 2.5 mg, moves to 5 mg, then stays at 7.5 mg or higher with on-time refills would pay $299 + $399 + 9 × $449 = $4,739 for 11 fills. Those 11 fills cover 308 days of doses.
Does Medicare cover Zepbound?
Only through the Medicare GLP-1 Bridge, and only for the KwikPen. According to Medicare.gov, the Bridge charges eligible Part D enrollees a $50 copay for a month's supply from July 1, 2026 through December 31, 2027. Zepbound single-dose vials and pens are excluded.
The eligibility rules carry a trap for Zepbound users. People with moderate-to-severe sleep apnea are not eligible for the Bridge, even though sleep apnea is one of Zepbound's approved uses. People with type 2 diabetes or fatty liver disease are also excluded. Medicare.gov says their Part D plan "might cover" a GLP-1 instead. More detail: Medicare Part D and GLP-1s.
How much weight did people lose in the trials?
In SURMOUNT-1 (the label's Study 1), adults without diabetes on 15 mg lost a mean 20.9% of body weight at 72 weeks, versus 3.1% on placebo. That figure uses the treatment-regimen estimand, which counts everyone randomized whether or not they kept taking the drug. The 5 mg and 10 mg groups lost 15.0% and 19.5%.
These are trial averages, not a promise. Individual results in the trial varied widely, and the participants also received diet and activity counseling.
Is compounded tirzepatide the same as Zepbound?
No. Compounded tirzepatide is made with the drug in Zepbound, but it is not the same product and it is not FDA-approved. FDA does not review compounded versions for safety, effectiveness or quality before they are sold. Compounded tirzepatide usually costs less than the self-pay KwikPen, which is why it is widely marketed. If you are weighing the two, start with compounded vs brand GLP-1s.
Frequently asked questions
How much does Zepbound cost without insurance?
Without insurance, Lilly's self-pay offer for the Zepbound KwikPen is $299 for a month of 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg when each refill is bought within 45 days, otherwise $499 at 7.5 mg and $699 at 10 to 15 mg, per Lilly's terms read October 15, 2026. A month means 28 days, the savings card allows 11 fills a calendar year, and the savings end December 31, 2026. Eleven fills at $449 come to $4,939, and because each fill covers 28 days they last 308 days, not a full year. Compounded tirzepatide is cheaper but is not FDA-approved.
Is Zepbound approved for sleep apnea?
Yes. Since December 20, 2024, Zepbound has been FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and activity changes. The approval rested on two 52-week trials in 469 adults without type 2 diabetes. The label lists 10 mg or 15 mg weekly as the maintenance dose for this use. It does not replace a sleep study or other treatment your clinician recommends.
What doses does Zepbound come in?
Every Zepbound form comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. The label starts everyone at 2.5 mg weekly for 4 weeks, then 5 mg, with further 2.5 mg steps no sooner than every 4 weeks. The maximum is 15 mg once a week. Your prescriber decides whether and when to increase.
Can I get Zepbound vials through the Medicare Bridge?
No. Medicare.gov says the GLP-1 Bridge covers Zepbound only as the KwikPen; single-dose vials and single-dose pens are excluded. The Bridge also covers Wegovy and Foundayo. Eligible Part D enrollees pay $50 for a month's supply from July 1, 2026 through December 31, 2027, but people with sleep apnea, type 2 diabetes or fatty liver disease are not eligible.
Why does the self-pay price jump if I refill late?
Lilly's terms, read October 15, 2026, give the $449 price at 7.5 mg to 15 mg only when each refill is bought within 45 days of the last one. Miss that window and the price rises to $499 at 7.5 mg or $699 at 10 mg to 15 mg. The 2.5 mg and 5 mg prices do not depend on the window.
Who should not take Zepbound?
The label says not to use Zepbound if you or a family member has had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious allergic reaction to tirzepatide or its ingredients. It also carries warnings for pancreatitis, gallbladder disease, kidney injury from dehydration and pregnancy. Discuss your full history with your prescriber.
Is Zepbound the same as Mounjaro?
Both contain tirzepatide and share the same strengths and injection forms, but they carry different FDA labels. Zepbound is approved for weight management and sleep apnea; Mounjaro is approved for type 2 diabetes and, for adults with type 2 diabetes at high risk, for lowering cardiovascular event risk. Insurance coverage usually follows the approved use, so the brand name matters for payment.
Sources
- FDA label (DailyMed): Zepbound prescribing information — label revised 08/2026 (SPL effective August 28, 2026); sections 1, 2, 3, 5, 6.1, 14 read 2026-11-08
- Drugs@FDA: Zepbound (NDA 217806) — original approval November 8, 2023; queried 2026-11-08
- FDA: FDA approves first medication for obstructive sleep apnea — press release December 20, 2024; read 2026-11-08
- Medicare.gov: Weight loss drugs (Medicare GLP-1 Bridge) — copay, dates, KwikPen-only coverage and exclusions; read 2026-11-08
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216 — published July 21, 2022; abstract read 2026-11-08
- Lilly: LillyDirect Zepbound self-pay terms — prices and refill rules read 2026-10-15; re-read blocked 2026-11-08
Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.
Check NexLife's plans and state availability → See the price index